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Massively-parallel sequencingMucolipidosis II alpha/beta (ML II alpha/beta; I-cell disease) is a rare, inherited, metabolic disease and has often
been clinically misdiagnosed. ML II alpha/beta results from a deﬁciency of the enzyme N-acetylglucosamine-
1-phosphotransferase (GlcNAc-PT), which causes the lysosomal enzymes to accumulate in plasma. We identiﬁed
two new Chinese patients with ML II alpha/beta by lysosomal enzyme assay. Using targeted next-generation se-
quencing genetic analysis, we located two homozygous nonsense mutations in the GNPTAB gene, c.1071G>A
(p.W357X) and c.1090C>T (p.R364X). These results were conﬁrmed by Sanger sequencing. To our knowledge,
the c.1071G>A mutation has not been previously reported. Our ﬁndings add to the number of reported cases of
this rare illness and to the GNPTAB pathogenic mutation database. This work also demonstrates the application
of lysosomal enzyme assay and targeted next-generation sequencing for the genetic screening analysis and diag-
nosis of ML II alpha/beta.
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rights reserved.1. Introduction
Mucolipidosis II alpha/beta (ML II alpha/beta; I-cell disease; OMIM
#252500) is a rare, autosomal recessive disorder caused by impaired
trafﬁcking of lysosomal hydrolases to lysosomes [1,2]. Mutations of
the GNPTAB gene cause functional deﬁcits in the N-acetylglucosamine-
1-phosphotransferase enzyme (EC 2.7.8.17), which is responsible for
the phosphorylation of mannose residues to mannose-6-phosphate
(M6P) on newly synthesized lysosomal enzymes in theGolgi apparatus.
Without the M6P to recruit synthesized lysosomal enzymes to the
Fig. 1. Clinical features of the two Chinese patients with ML II alpha/beta. For Patient 1: (A–B) A “coarse” face was noted with a low nasal bridge, inner epicanthic folds, gum hy-
pertrophy, and partially erupted teeth. (C) Patient 1 had broad wrists bilaterally. (D–E) Radiographs of Patient 1 showed multiple dysostosis including generalized osteopenia,
oar-shaped ribs, and scoliosis. For Patient 2: (F) He had noted “coarsening” of face with narrow forehead, thin eyebrows, low nasal bridge, long philtrum, open mouth. (G–H) Patient
2 also had broadening of wrists and ﬁngers, a deformed chest. (I–J) Dysotosis multiplex (short, thick clavicles, thick elevated scapula with poorly formed glenoid fossa, oar-shaped
ribs, and scoliosis) in Patient 2.
170 Y. Yang et al. / Genomics 102 (2013) 169–173lysosomes, the enzymes are secreted from the Golgi to the extracellular
space [3,4]. As a result, these substances accumulate and cause the
symptoms of the disease, ML II alpha/beta is characterized by failure
to thrive and developmental delays and manifests as thickened skin,
coarse facial features, hypertrophic gingiva, thoracic deformity, kypho-
sis, clubfeet, and restricted joint movement [5]. Patients with ML II
alpha/beta usually die before seventh year of age from cardiorespiratory
failure or recurrent respiratory tract infections [6].
N-acetyglucosamine-1-phosphotransferase is a heterohexamer
(α2β2γ2) composed of six subunits. The subunits α and β are
encoded by the GNPTAB gene and the γ subunit is encoded by the
GNPTG gene [7,8]. Mucolipidosis II alpha/beta and III alpha/beta are
caused bymutations in the GNPTAB gene [9,10], whereas mucolipidosis
III gamma results from the mutations in the GNPTG gene [11]. While
more than 60 different mutations in the GNPTAB gene have been
reported [10,12–18], there is only one reportedML II alpha/beta patient
from China. This patient had two compound heterozygous mutations:
c.2422delC in exon 13, which was a novel mutation, and c.3565C>T in
exon 19, which had been previously reported [17,19].
Sanger sequencing is the traditional method for identifying these
mutations and has been used as gold standard of sequencing for
more than three decades. Nevertheless, Sanger sequencing for thisTable 1
Lysosomal enzymes activity in plasma.
Enzyme Enzyme activity (nmol/1 h/ml)
Patient 1 Patient 2 Normal range
β-Mannosidase 2410 3142 65–360
β-galactosidase 148 115 0–18.7
β-glucuronidase 288.6 325 3.7–11.2
α-L-fucosidase 119.2 132 5–23
Hexosaminidase 3284 3626 60–500screening purposes has relatively high cost and low throughput,
which greatly limits its use. SinceML II alpha/beta is oftenmisdiagnosed
because of its complicated clinical and radiographic features, often
many different gene tests need to be conducted before the ﬁnal diagno-
sis can be made.
Here we describe the clinical and biochemical ﬁndings of two new
cases of ML II alpha/beta from China. Genetic analysis of GNPTAB was
carried out by targeted next-generation sequencing in the two pa-
tients and conﬁrmed.2. Materials and methods
This study was approved by the Medical Ethics Committee of Gen-
eral Hospital of Beijing Military Region and informed consents were
signed by the participants' legal guardian. The activity of several lyso-
somal enzymes in serum was assayed using methylumbelliferone
(MU)-labeled ﬂuorescent substrate. Genomic DNA from peripheral
blood leukocytes derived from the affected individuals and the avail-
able family members was extracted using the QIAamp DNA Blood
Midi Kit (Qiagen, Hilden, Germany). The list of 505 inheritable genetic
disease related genes in the panel for captured and targeted next-
generation sequencing can be seen in Supplementary Table 1. The
exon regions of 505 genes including GNPTAB were speciﬁcally
enriched using biotinylated capture probe (MyGenostics, Baltimore,
MD, USA) as described previously [20,21]. In brief, 1 μg DNA library
was mixed with Buffer BL and GenCap probe (MyGenostics, MD,
USA), heated at 95 °C for 7 min and 65 °C for 2 min on a PCR ma-
chine; 23 μL of the 65 °C pre-warmed Buffer HY (MyGenostics, MD,
USA) was then added to the mix. The mixture was held at 65 °C for
22 h with PCR lid heat on for hybridization. Fifty microliters of
MyOne beads (Life Technologies Corporation, USA) were washed in
500 μL 1 × binding buffer 3 times and resuspended in 80 μL
1 × binding buffer. Sixty-four μL 2 × binding buffer was added to
the hybrid mix and transferred to the tube with 80 μL MyOne
Fig. 2. Identiﬁcation of two homozygous nonsense mutations of GNPTAB gene in two Chinese patients with mucolipidosis II alpha/beta using targeted next-generation sequencing.
(A) Homozygous nonsense mutation c.1071G>A in Patient 1. (B) Homozygous nonsense mutation c.1090C>T in Patient 2.
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washed once with WB1 buffer at room temperature for 15 min and
three times with WB3 buffer at 65 °C for 15 min. The bound DNA
was then eluted with eluting buffer. The eluted DNA was ﬁnally am-
pliﬁed for 15 cycles using the following program: 98 °C for 30 s
(1 cycle); 98 °C for 25 s, 65 °C for 30 s, 72 °C for 30 s (15 cycles);
72 °C for 5 min (1 cycle). The PCR product was puriﬁed using SPRI
beads (Beckman Coulter, Inc.) according to manufacturer's protocol.
The enrichment libraries were sequenced on Illumina HiSeq 2000 se-
quencer for paired read 100 bp.
Short read mapping and alignment were performed using BWA
software (Burrows Wheeler Aligner). SNPs and indels were detected
using the SOAPsnp software and GATK Indel Genotyper (http://
www.broadinstitute.org/gsa/wiki/index.php/; The Genome Analysis
Toolkit), respectively. All reference sequences were based on the
NCBI37/hg19 assembly of the human genome.
To conﬁrm the two variants identiﬁed by next-generation se-
quencing, the exon 9 of GNPTAB was ampliﬁed with forward primer
5′-CAGACGGGCAGAAGGAAAGG-3′ and reverse primer 5′-GCCTGATA
TTTGACTACAGTAGT-3′. The PCR products were sequenced by direct
cycle sequencing using Big Dye Terminator Cycle Sequencing Ready
Reaction Kit (Applied Biosystems) and analyzed on ABI Prism®
3130 Genetic Analyser (Applied Biosystems, Foster City, CA, USA).
To detect c.1071G>A (p.W357X), genomic DNA samples were am-
pliﬁed using a sense primer 5′-CGAGAGGCATGCACCATGGGTT-3′ and
an antisense primer 5′-GAGAGTGAATGAGAGCTGTTTGG-3′. The prod-
ucts were digestedwithHpy188III. To detect c.1090C>T (p.R364X), ge-
nomic DNA samples were ampliﬁed with the same primers as
c.1071G>A. The product was digested with TaqI. All the digested frag-
ments were separated on 3% agarose gel.Table 2
The coverage statistics of each exon by next generation sequencing in two ML II alpha/beta
Sample Target region
bases (bp)
Base covered on
target (bp)
Coverage of
target region
Average sequencing
depth on target
Patient1 5615 5615 100.00% 153
Patient2 5615 5615 100.00% 1803. Results
3.1. Clinical features of the two patients with ML II alpha/beta
3.1.1. Patient 1
Patient 1 is female, born at 40 weeks gestation age by cesarean sec-
tion deliverywith a birthweight of 3000 g and length of 50 cm. Her par-
ents are of Han descent and she was their ﬁrst child. At the patient
presented at 1 year, 5 months of age with developmental delay. She
was unable to sit fully without support, had poor sucking and spoke
only one phrase, “baba mama”. Physical examination showed her head
circumference was 43 cm, body weight 9.5 kg, length 77.4 cm (25th
centile). A “coarse” face was noted with a low nasal bridge, inner
epicanthic folds, gum hypertrophy, and partially erupted teeth. She had
broad wrists bilaterally with limited knee and hip joint ﬂexion, and an
umbilical hernia. Skeletal survey showed multiple dysostosis including
generalized osteopenia, oar-shaped ribs, and scoliosis (Figs. 1A–E).3.1.2. Patient 2
Patient 2 is male, born at 37 weeks gestation by vaginal delivery with
a low birth weight 2100 g (10th centile). He presented at 11 months
with severe developmental delay and hypotonia. He did not have head
control and was not able to sit and stand, roll over, or speak. He had
noted “coarsening” of face with narrow forehead, thin eyebrows, low
nasal bridge, long philtrum, openmouth. Patient 2 also had a broadening
of wrists and ﬁngers, a deformed chest, and dysotosis multiplex (short,
thick clavicles, thick elevated scapula with poorly formed glenoid fossa,
oar-shaped ribs, and scoliosis). Cardiac sonography showedmild left ven-
tricular hypertrophy and abdominal sonography showed hepatomegalypatients.
Fraction of target covered
with at least 4×
Fraction of target covered
with at least 10×
Fraction of target covered
with at least 20×
100.00% 100.00% 100.00%
100.00% 100.00% 100.00%
Fig. 3. Average coverage of each exon of GNPTAB gene.
172 Y. Yang et al. / Genomics 102 (2013) 169–173with increased density (Figs. 1F–J). Chromosome karotyping showed 46,
XY.
3.2. Lysosomal enzyme activity assays
The results of lysosomal enzyme activity assays in plasma are shown
in Table 1. In each case, markedly increase of multiple lysosomal en-
zymes activity in plasma conﬁrmed the diagnosis of ML II alpha/beta.
3.3. Identiﬁcation of two GNPTAB mutations
The 505 inheritable genetic disease related genes were captured
and sequenced by next generation sequencing on two patients. All
coding variants including non-synonymous, indel and splice-site var-
iants found through the bioinformatic analysis were listed in Supple-
mentary Table 2. The variants were ﬁltered out if they showed up in
the 1000 genome database and the dbSNP database (Supplementary
Table 3). After the ﬁltration, only two predicted homozygous patho-
genic mutations in the GNPTAB gene were identiﬁed, c.1071G>A
(p.W357X) in Patient 1 (Fig. 2A) and c.1090C>T (p.R364X) in Patient
2 (Fig. 2B). All the GNPTAB gene exons for both patients were well
covered by next generation sequencing data. The coverage statistics
of each exon was shown in Table 2, and the average coverage of
each exon was shown in Fig 3.
The two variants identiﬁed using next-generation sequencing
were conﬁrmed by Sanger sequencing (Figs. 4A and B) and restriction
enzyme analysis (Figs. 4C and D). Additional testing revealed that
parents of both patients were showed heterozygous for the respective
mutations. The two nonsense mutations were not found in 100
healthy controls by direct sequencing.
4. Discussion
ML II alpha/beta is very rare and often misdiagnosed, usually as a
one of the mucopolysaccharidoses. The clinical and radiographic fea-
tures of ML II alpha/beta are similar to those of mucopolysaccharidosis
type 1H (MPS 1H; Hurler syndrome). Overlapping clinical phenotypes
of mucolipidosis (ML) and mucopolysaccharidoses (MPS) make
distinguishing between these diseases a diagnostic challenge for the cli-
nician. The two cases reported in this study were diagnosed as ML II
alpha/beta primarily because of the age of onset and the rapid, progres-
sive and severe disease course. One useful diagnostic tool to differenti-
ate mucolipidosis from mucopolysaccharidoses is that mucolipidosisresults in signiﬁcantly elevated lysosomal enzyme activity in plasma,
but normal urinary levels of acidmucopolysaccharides [22]. The twopa-
tients here are diagnosed as Mucolipidosis based on the marked in-
crease of multiple lysosomal enzyme activity in plasma and normal
acid mucopolysaccharides in urine.
ML II alpha/beta and ML III alpha/beta are allelic and both result
from defects in the GNPTAB gene. ML II alpha/beta hasmore severe clin-
ical coursewith onset at birth and fatal outcomeoften in theﬁrst decade
of life [6]. Recent genetic studies suggest that there is an genotype–
phenotype correlation between the ML II alpha/beta and the milder
ML III alpha/beta. ML II alpha/beta is often caused by two severe muta-
tions that completely inactivate GlcNAc-phosphotransferase, whereas
ML III alpha/beta is caused by at least one mild mutation that can pro-
duce active GlcNAc-phosphotransferase [13,23,24]. We identiﬁed two
homozygous nonsense mutations of the GNPTAB gene in two unrelated
Chinese families withML II alpha/beta. The two nonsensemutations are
presumed to result in premature termination of protein translation at
the exon 9 of GNPTAB gene, and predicted to produce no functional
N-acetyglucosamine-1-phosphotransferase. The homozygousmutation
for c.1090C> (p.R364X) has been recently reported in a patientwithML
II alpha/beta [23], and compound heterozygous mutation in a patient
with ML III alpha/beta. The c.1071G>A (p.W357X) mutation has not
been reported previously or included in mutation databases.
Targeted sequence capture and next-generation sequencing has
been employed for genetic analysis of inherited metabolic diseases,
such as MPS [25,26], ML III gamma [27], mitochondria disorders [28].
In this study, we used targeted sequence capture and next-generation
sequencing technology to detect candidate mutations of GNPTAB gene
from patients with mucolipidosis. All the base pairs of target exons
andﬂanking regionswere successfully sequenced and two homozygous
nonsense mutations resulting in premature truncation of GNPTAB pro-
tein were identiﬁed. Next-generation sequencing technologies are ef-
fective for genetic diagnosis of mucolipidosis and may represent a
superior technique to Sanger method for screening and testing pur-
poses in terms of cost, time, and convenience.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ygeno.2013.06.001.
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Fig. 4. Two nonsense mutations were conﬁrmed by Sanger sequencing and restriction
enzyme analysis. (A) Homozygous nonsense mutations c.1071G>A (p.W357X) was
detected in Patient 1 by direct sequencing of exon 9 of GNPTAB. (B) Homozygous non-
sense mutations c.1090C>T (p.R3764X) was detected in Patient 2 by direct sequencing
of exon 9 of GNPTAB. (C) PCR product from Patient 1 with c.1071G>A was digested
with Hpy188III, and the ampliﬁed fragment from normal control was not digested
with Hpy188III. (D) PCR product from Patient 2 with c.1090C>T was not digested
with TaqI, and the ampliﬁed product form normal control could be digested with
TaqI. M, DNA marker DL2000; NC, normal control; Pt1, Patient 1; Pt2, Patient 2.
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